Merck, 119114-5MG, Luciferase Inhibitor II

General description
A 2-arylbenzothiazole compound that acts as an inhibitor against the ATP-dependent Photinus pyralis (lucPpy) and Photuris pennsylvanica (lucPpe) luciferase activity (IC₅₀ = 0.2 and 0.32 µM, respectively, with 10 µM ATP, 10 µM luciferin, and 10 nM respective enzyme). Unlike Luciferase Inhibitor I (Cat. No. 119113), Luciferase Inhibitor II is competitive with respect to luciferin and exhibits reduced potency against lucPpe-based commercial luciferase-luciferin formulations with high luciferin concentration (IC₅₀ = 10 µM against Promega′s Kinase-Glo; ineffective against Kinase-Glo Plus and Kinase-Glo Max; at a 3-fold formulation dilution and 6.77 µM ATP).
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Auld, D.S., et al. 2009. J. Med. Chem.52, 1450.
Auld, D.S., et al. 2008. J. Med. Chem.51, 2372.
Legal Information
Marketed by Promega Corp. under the registered trademarks.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Harmful (C)